Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA approves Orilissa for moderate to severe endometriosis pain

July 25, 2018

BDNF gene therapy shows promising preclinical results and prepares for clinical trials

July 25, 2018

New phase IIa study aims to confirm absence of anticholinergic effects with seliforant

July 25, 2018

Selective SSTR4 receptor agonist presented for the treatment of Alzheimer's disease

July 25, 2018

Kinase inhibitor restores chemo sensitivity

July 25, 2018

Interneurons to the spinal cord rescue

July 25, 2018

Active substance in ROSgard protects kidney tissue in preclinical acute kidney injury study

July 24, 2018

Phase III study of Revlimid in relapsed/refractory indolent lymphoma meets primary endpoint

July 24, 2018

Medshine Discovery identifies new EGFR inhibitors

July 24, 2018

Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine patent oxytocin receptor antagonists

July 24, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
Alicorn synthesizes new AAK1 inhibitors
BioWorld Science
Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...